Pharma Two B – Developing Innovative Pharmaceutical Products

Pharma Two B

About Us
Why P2B001
About PD
News & Events
- Press Releases
- Events
Contact Us

Optimizing

the treatment of Parkinson’s disease

Improved

* As demonstrated in Phase III clinical study motor symptoms and daily function*

Good tolerability

* As demonstrated in Phase III clinical study and safety*

Once-daily capsule

no need for titration

P2B001 Completed

Phase 3 Study in Early PD

OUR COMPANY

We are striving to improve patients’ quality of life by developing innovative combination products, based on previously approved drugs, with favorable balance between safety and efficacy.

WHAT IS P2B001?

P2B001 is a novel, once-daily combination of extended-release (ER) pramipexole, a low dose dopamine agonist (0.6mg), and rasagiline, a low dose MAO-B inhibitor (0.75mg), developed specifically for the treatment of..

LATEST NEWS

Pharma Two B Announces Publication of Positive Phase 3 Study Results of P2B001, an Investigational Treatment for Early Parkinson’s Disease, in Movement Disorders

November 9, 2023

Pharma Two B to Present Additional Phase 3 Positive Results of P2B001, a once-daily, fixed-dose combination of low-dose pramipexole and low-dose rasagiline, at 2023 International Congress of Parkinson’s Disease and Movement Disorders®

August 28, 2023

Pharma Two B to Present Additional Positive Results from P2B001 Phase 3 Trial at 2023 American Academy of Neurology Annual Meeting

April 23, 2023

OUR MISSION

We are striving to improve patients’ quality of life by developing innovative combination products, based on previously approved drugs,
with favorable balance between safety and efficacy.

Thank you!

An email was sent with access to our exclusive materials.
Please check your inbox and spam folder.

Please subscribe for this

Get this exclusive content straight to your email

Name